ARCHOS Group: Hyper Growth in turnover in the first half of 2024

The ARCHOS group (ISIN code: FR001400KO61 ALJXR) recorded a turnover of €16.5 million for the first half of 2024, compared to €8.7 million for the same semester in 2023, marking an increase of 90%. This result comes in particular from the integration of the Elexo company within Logic Instrument.

In the Defense and Industrial segment, the addition of Elexo strengthened the product offering. For medical devices, the companies DOMISANTE, Dextrain and Poladerme began marketing after three years of development. Finally, ARCHOS launched a new range of tablets in June 2024, including the ARCHOS T105 FHD 4G.

For 2024, ARCHOS plans to continue to enrich its Defense solutions, expand its customer base and invest in reindustrialization. In the medical field, Dextrain, Poladerme and DOMISANTE are accelerating their development among home health players. The new range of tablets will be available during the summer and an animal welfare offer is expected at the end of the year.